MUC1 drives c-Met-dependent migration and scattering

Molecular Cancer Research

Volumn 10, Issue 12, 2012, Pages 1544-1554

  Horm, Teresa M ^a   Bitler, Benjamin G ^b   Broka, Derrick M ^b   Louderbough, Jeanne M ^b   Schroeder, Joyce A ^a,b,c  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MUC1 INHIBITORY PEPTIDE; MUCIN 1; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BT20 CELL; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MDA MB 231 CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MUCIN-1; NEOPLASM METASTASIS; PEPTIDES; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION, GENETIC;

EID: 84871361268     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0296     Document Type: Article

References (55)

1. Baldus SE, Wienand JR, Werner JP, Landsberg S, Drebber U, Hanisch FG, et al. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int J Oncol 2005;27:1289-97.
2. Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 2002;32:525-9. (Pubitemid 43102758)
3. Guddo F, Giatromanolaki A, Patriarca C, Hilkens J, Reina C, Alfano RM, et al. Depolarised expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res 1998;18:1915-20. (Pubitemid 28344849)
4. Xu H, Inagaki Y, Seyama Y, Hasegawa K, Sugawara Y, Du G, et al. Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with beta-catenin in tumor progression. Life Sci 2011;88:1063-9.
5. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 1996;49:560-4. (Pubitemid 26232730)
6. Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, et al. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchows Arch 2011;458:615-20.
7. Zhang HK, Zhang QM, Zhao TH, Li YY, Yi YF. Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance. World J Gastroenterol 2004;10:3044-7.
8. Hinoda Y, Ikematsu Y, Horinochi M, Sato S, Yamamoto K, Nakano T, et al. Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol 2003;38:1162-6. (Pubitemid 38128828)
9. Arai T, Fujita K, Fujime M, Irimura T. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol 2005;12:654-61. (Pubitemid 41725491)
10. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC, et al. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010;201:102-10.
11. Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, et al. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 2007;105:695-702. (Pubitemid 46734194)
12. Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F, et al. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 2006;1:46-51. (Pubitemid 47164020)
13. Matsuda K, Masaki T, Watanabe T, Kitayama J, Nagawa H, Muto T, et al. Clinical significance of MUC1 and MUC2 mucin and p53 protein expression in colorectal carcinoma. Jpn J Clin Oncol 2000;30:89-94.
14. Raina D, Ahmad R, Chen D, Kumar S, Kharbanda S, Kufe D, et al. MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther 2008;7:1959-67.
15. Wei XL, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 2006;21:295-305. (Pubitemid 43099944)
16. Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L, et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem 2001;276:35239-42.
17. Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, et al. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res 2009;69:6799-806.
18. Rahn JJ, Chow JW, Horne GJ, Mah BK, Emerman JT, Hoffman P, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 2005;22:475-83. (Pubitemid 41750699)
19. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129:255-65.
20. Ye Q, Yan Z, Liao X, Li Y, Yang J, Sun J, et al.MUC1induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab Invest 2011;91:778-87.
21. Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011;30:1449-59.
22. Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC, et al. MUC1 overexpression results inmammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004;23:5739-47. (Pubitemid 39093019)
23. Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi MD, et al. MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem 2012;287:10703-13.
24. Ahmad R, Raina D, Joshi MD, Kawano T, Ren J, Kharbanda S, et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaBp65 transcription factor. Cancer Res 2009;69:7013-21.
25. Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B, et al. MUC1- C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal 2011;4:1-14.
26. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation ill the mouse mammary gland. J Biol Chem 2001;276:13057-64.
27. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001;276:6061-4.
28. Yamamoto M, Bharti A, Li Y, Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 1997;272:12492-4. (Pubitemid 27203339)
29. Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of erbB1 receptor trafficking. Oncogene 2007;26:1693-701. (Pubitemid 46426203)
30. Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci 2010;123:1716-23.
31. Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor alpha-dependent cancer progression is modulated by Muc1. Cancer Res 2007;67:6591-8. (Pubitemid 47105503)
32. Li YQ, Kufe D. The human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). Biochem Biophys Res Commun 2001;281:440-3. (Pubitemid 32928175)
33. Ren J, Raina D, Chen W, Li G, Huang L, Kufe D, et al. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res 2006;4:873-83. (Pubitemid 44877017)
34. Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, et al. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 2007;67:5201-10. (Pubitemid 46997258)
35. Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D, et al. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 2006;25:20-31. (Pubitemid 43050000)
36. Dietz GPH, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004;27:85-131. (Pubitemid 39370094)
37. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72. (Pubitemid 29420581)
38. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 2001;61:474-7. (Pubitemid 32128600)
39. Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 2009;15:100-9.
40. Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM, et al. Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells. Mol Cancer Ther 2011;10:2062-71.
41. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
42. Imaizumi Y, Murota H, Kanda S, Hishikawa Y, Koji T, Taguchi T, et al. Expression of the c-Met proto-oncogene and its possible involvement in liver invasion in adult T-cell leukemia. Clin Cancer Res 2003;9:181-7. (Pubitemid 36109731)
43. Kawataki T, Yamane T, Naganuma H, Rousselle P, Andurén I, Tryggvason K, et al. Laminin isoforms and their integrin receptors in glioma cell migration and invasiveness: Evidence for a role of alpha5-laminin (s) and alpha3beta1 integrin. Exp Cell Res 2007;313:3819-31. (Pubitemid 47566379)
44. Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, et al. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J Biol Chem 2008;283:26985-95.
45. Yang E, Hu XF, Xing PX. Advances of MUC1 as a target for breast cancer immunotherapy. Histol Histopathol 2007;22:905-22. (Pubitemid 47034157)
46. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
47. Hu XF, Yang E, Li J, Xing PX. MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Rev Anticancer Ther 2006;6:1261-71. (Pubitemid 44304694)
48. Yuan Z, Wong S, Borrelli A, Chung MA. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun 2007;362:740-6. (Pubitemid 47368156)
49. Matsubara D, Ishikawa S, Sachiko O, Aburatani H, Fukayama M, Niki T, et al. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol 2010;177:2191-204.
50. Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009;69:5133-41.
51. Zhang L, Gallup M, Zlock L, Basbaum C, Finkbeiner WE, McNamara NA. Cigarette smoke disrupts the integrity of airway adherens junctions through the aberrant interaction of P120-catenin with the cytoplasmic tail of MUC1. J Pathol 2012 Jul 26. [Epub ahead of print].
52. Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 2000;88:507-18.
53. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25. (Pubitemid 37493640)
54. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
55. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008;7:3499-508.